Recent developments in the pathogenesis of pruritus in bullous pemphigoid.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
04
03
2021
received:
09
11
2020
accepted:
23
03
2021
pubmed:
27
5
2021
medline:
17
11
2021
entrez:
26
5
2021
Statut:
ppublish
Résumé
Bullous pemphigoid (BP) is a common autoimmune bullous disease which mainly affects the elderly. The incidence of BP is gradually increasing and associated with high mortality. This disease is clinically characterized by intensely pruritic and widespread bullous lesions. Alternative therapy options for pruritus in patients with BP are limited primarily because pathophysiological mechanisms of itching in BP are still unclear. This review aims to explain crucial concepts of the pathogenesis of pruritus in BP. Vital findings in recent years will be summarized, and cofactors of the pathogenesis of pruritus will be discussed in detail. We will summarize knowledge on pathogenic factors in the immunologic level conducing to skin pruritus in BP.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1441-1448Subventions
Organisme : The Nanjing Incubation Program for National Clinical Research Center
ID : 2019060001
Organisme : The CAMS Innovation Fund for Medical Sciences
ID : CIFMS-2017-I2M-1-017
Informations de copyright
© 2021 the International Society of Dermatology.
Références
Miyamoto D, Santi CG, Aoki V, et␣al. Bullous pemphigoid. An Bras Dermatol 2019; 94: 133-146.
Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332.
Schmidt T, Sitaru C, Amber K, et␣al. BP180- and BP230-specific IgG autoantibodies in pruritic disorders of the elderly: a preclinical stage of bullous pemphigoid? Br J Dermatol 2014; 171: 212-219.
Rüdrich U, Gehring M, Papakonstantinou E, et␣al. Eosinophils are a major source of interleukin-31 in bullous pemphigoid. Acta Derm Venereol 2018; 98: 766-771.
Simon D, Borradori L, Simon HU. Eosinophils as putative therapeutic targets in bullous pemphigoid. Exp Dermatol 2017; 26: 1187-1192.
de Graauw E, Sitaru C, Horn M, et␣al. Evidence for a role of eosinophils in blister formation in bullous pemphigoid. Allergy 2017; 72: 1105-1113.
Kridin K. Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation. Br J Dermatol 2018; 179: 1141-1147.
Dresow SK, Sitaru C, Recke A, et␣al. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol 2009; 160: 429-432.
Cozzani E, Gasparini G, Di Zenzo G, et␣al. Immunoglobulin E and bullous pemphigoid. Eur J Dermatol 2018; 28: 440-448.
Lin L, Hwang B-J, Culton DA, et␣al. Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid. J Invest Dermatol 2018; 138: 1032-1043.
Messingham KN, Holahan HM, Frydman AS, et␣al. Human eosinophils express the high affinity IgE receptor, FcepsilonRI, in bullous pemphigoid. PLoS One 2014; 9: e107725.
Foster EL, Simpson EL, Fredrikson LJ, et␣al. Eosinophils increase neuron branching in human and murine skin and in␣vitro. PLoS One 2011; 6: e22029.
Lee JJ, Protheroe CA, Luo H, et␣al. Eosinophil-dependent skin innervation and itching following contact toxicant exposure in mice. J Allergy Clin Immunol 2015; 135: 477-487.
Lee EH, Kim YH, Kim S, et␣al. Usefulness of enzyme-linked immunosorbent assay using recombinant BP180 and BP230 for serodiagnosis and monitoring disease activity of bullous pemphigoid. Ann Dermatol 2012; 24: 45-55.
Patsatsi A, Kyriakou A, Pavlitou-Tsiontsi A, et␣al. Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid. Clin Dev Immunol 2012; 2012: 854795.
Bardazzi F, Barisani A, Magnano M, et␣al. Autoantibody serum levels and intensity of pruritus in bullous pemphigoid. Eur J Dermatol 2016; 26: 390-391.
Daneshpazhooh M, Ghiasi M, Lajevardi V, et␣al. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid. Arch Dermatol Res 2018; 310: 255-259.
van Beek N, Lüttmann N, Huebner F, et␣al. Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol 2017; 153: 30-38.
Hashimoto T, Ohzono A, Teye K, et␣al. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid. Br J Dermatol 2017; 177: 141-151.
Messingham KN, Crowe TP, Fairley JA. The intersection of IgE autoantibodies and eosinophilia in the pathogenesis of bullous pemphigoid. Front Immunol 2019; 10: 2331.
Cozzani E, Parodi A, Rebora A, et␣al. Bullous pemphigoid in Liguria: a 2-year survey. J Eur Acad Dermatol Venereol 2001; 15: 317-319.
Kalowska M, Ciepiela O, Kowalewski C, et␣al. Enzyme-linked immunoassay index for anti-NC16a IgG and IgE auto-antibodies correlates with severity and activity of bullous pemphigoid. Acta Derm Venereol 2016; 96: 191-196.
Zone JJ, Taylor T, Hull C, et␣al. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 2007; 127: 1167-1174.
Freire PC, Munoz CH, Stingl G. IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants. Br J Dermatol 2017; 177: 1644-1653.
Holgate S, Bousquet J, Wenzel S, et␣al. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001; 17: 233-240.
Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 2001; 164: S6-11.
Fairley JA, Baum CL, Brandt DS, et␣al. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009; 123: 704-705.
Kremer N, Snast I, Cohen ES, et␣al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol 2019; 20: 209-216.
Murrell DF, Daniel BS, Joly P, et␣al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012; 66: 479-485.
Lotts T, Stander S. Research in practice: substance P antagonism in chronic pruritus. J Dtsch Dermatol Ges 2014; 12: 557-559.
Mashaghi A, Marmalidou A, Tehrani M, et␣al. Neuropeptide substance P and the immune response. Cell Mol Life Sci 2016; 73: 4249-4264.
Marriott I, Bost KL. IL-4 and IFN-gamma up-regulate substance P receptor expression in murine peritoneal macrophages. J Immunol 2000; 165: 182-191.
Lai JP, Douglas SD, Ho WZ. Human lymphocytes express substance P and its receptor. J Neuroimmunol 1998; 86: 80-86.
Weinstock JV, Blum A, Walder J, et␣al. Eosinophils from granulomas in murine schistosomiasis mansoni produce substance P. J Immunol 1988; 141: 961-966.
Metwali A, Blum A, Ferraris L, et␣al. Eosinophils within the healthy or inflamed human intestine produce substance P and vasoactive intestinal peptide. J Neuroimmunol 1994; 52: 69-78.
Stander S, Luger TA. NK-1 Antagonists and Itch. Handb Exp Pharmacol 2015; 226: 237-255.
Yosipovitch G, Rosen JD, Hashimoto T. Itch: From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol 2018; 142: 1375-1390.
Yosipovitch G, Ständer S, Kerby MB, et␣al. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. J Am Acad Dermatol 2018; 78: e10.
Ohanyan T, Schoepke N, Eirefelt S, et␣al. Role of substance P and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant. Acta Derm Venereol 2018; 98: 26-31.
Hashimoto T, Kursewicz CD, Fayne RA, et␣al. Pathophysiologic mechanisms of itch in bullous pemphigoid. J Am Acad Dermatol 2020; 83: 53-62.
Raap M, Rüdrich U, Ständer S, et␣al. Substance P activates human eosinophils. Exp Dermatol 2015; 24: 557-559.
Friedman S, Levi-Schaffer F. Substance P and eosinophils: an itchy connection. Exp Dermatol 2015; 24: 918-919.
Dillon SR, Sprecher C, Hammond A, et␣al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5: 752-760.
Meng J, Moriyama M, Feld M, et␣al. New mechanism underlying IL-31-induced atopic dermatitis. J Allergy Clin Immunol 2018; 141: e1678.
Takamori A, Nambu A, Sato K, et␣al. IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity. Sci Rep 2018; 8: 6639.
Feld M, Garcia R, Buddenkotte J, et␣al. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol 2016; 138(500-508): e524.
Bonciani D, Quintarelli L, Del Bianco E, et␣al. Serum levels and tissue expression of interleukin-31 in dermatitis herpetiformis and bullous pemphigoid. J Dermatol Sci 2017; 87: 210-212.
Salz M, Haeberle S, Hoffmann J, et␣al. Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE. J Dermatol Sci 2017; 87: 309-311.
Kunsleben N, Rüdrich U, Gehring M, et␣al. IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31. J Invest Dermatol 2015; 135: 1908-1911.
Kulczycka-Siennicka L, Cynkier A, Waszczykowska E, et␣al. The role of intereukin-31 in pathogenesis of itch and its intensity in a course of bullous pemphigoid and dermatitis herpetiformis. Biomed Res Int 2017; 2017: 5965492.
Bagci IS, Ruzicka T. IL-31: a new key player in dermatology and beyond. J Allergy Clin Immunol 2018; 141: 858-866.
Nattkemper L, Martinez-Escala M, Gelman A, et␣al. Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin. Acta Derm Venereol 2016; 96: 894-898.
Hofbauer G, Nobbe S, Dziunycz P, et␣al. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol 2012; 92: 24-28.
Kabashima K, Furue M, Hanifin JM, et␣al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol 2018; 142: e1127.
Teraki Y, Hotta T, Shiohara T. Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells. J Invest Dermatol 2001; 117: 1097-1102.
McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine 2015; 75: 38-50.
Nakayama T, Hirahara K, Onodera A, et␣al. Th2 cells in health and disease. Annu Rev Immunol 2017; 35: 53-84.
Russo R, Cozzani E, Gasparini G, et␣al. Targeting interleukin 4 receptor alpha: a new approach to the treatment of cutaneous autoimmune bullous diseases? Dermatol Ther 2020; 33: e13190.
Simpson EL, Gadkari A, Worm M, et␣al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol 2016; 75: 506-515.
Kaye A, Gordon SC, Deverapalli SC, et␣al. Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatol 2018; 154: 1225-1226.
Oetjen LK, Mack MR, Feng J, et␣al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 2017; 171(217-228): e213.
Castilow EM, Meyerholz DK, Varga SM. IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus␣vaccine-enhanced disease. J Immunol 2008; 180: 2376-2384.
Bao K, Reinhardt RL. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. Cytokine 2015; 75: 25-37.
Masuoka M, Shiraishi H, Ohta S, et␣al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest 2012; 122: 2590-2600.
Hashimoto T, Rosen JD, Sanders KM, et␣al. Possible roles of basophils in chronic itch. Exp Dermatol 2019; 28: 1373-1379.
Noguchi T, Nakagome K, Kobayashi T, et␣al. Periostin upregulates the effector functions of eosinophils. J Allergy Clin Immunol 2016; 138: e1445.
Nakashima C, Otsuka A, Kitoh A, et␣al. Basophils regulate the recruitment of eosinophils in a murine model of irritant contact dermatitis. J Allergy Clin Immunol 2014; 134: 100-107.
Raap U, Gehring M, Kleiner S, et␣al. Human basophils are a source of - and are differentially activated by - IL-31. Clin Exp Allergy 2017; 47: 499-508.
Salter BM, Oliveria JP, Nusca G, et␣al. Thymic stromal lymphopoietin activation of basophils in patients with allergic asthma is IL-3 dependent. J Allergy Clin Immunol 2015; 136: 1636-1644.
Brunner T, Heusser CH, Dahinden CA. Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. J Exp Med 1993; 177: 605-611.
Ochensberger B, Tassera L, Bifrare D, et␣al. Regulation of cytokine expression and leukotriene formation in human basophils by growth factors, chemokines and chemotactic agonists. Eur J Immunol 1999; 29: 11-22.
MacGlashan D Jr, White JM, Huang SK, et␣al. Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol 1994; 152: 3006-3016.
Gibbs BF, Haas H, Falcone FH, et␣al. Purified human peripheral blood basophils release interleukin-13 and preformed interleukin-4 following immunological activation. Eur J Immunol 1996; 26: 2493-2498.
Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol 2016; 51: 263-292.
Storan ER, O'Gorman SM, McDonald ID, et␣al. Role of cytokines and chemokines in itch. Handb Exp Pharmacol 2015; 226: 163-176.
Zeidler C, Pereira MP, Huet F, et␣al. Pruritus in autoimmune and inflammatory dermatoses. Front Immunol 2019; 10: 1303.
Ugajin T, Takahashi M, Miyagishi C, et␣al. A case of bullous pemphigoid associated with infiltration and activation of basophils. Br J Dermatol 2015; 173: 1095-1098.
Dimson OG, Giudice GJ, Fu CL, et␣al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol 2003; 120: 784-788.
Messingham KA, Holahan HM, Fairley JA. Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid. Immunol Res 2014; 59: 273-278.
Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol 2019; 10: 1238.
Izumi K, Nishie W, Mai Y, et␣al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol 2016; 136: 2201-2210.
Horikawa H, Kurihara Y, Funakoshi T, et␣al. Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. Br J Dermatol 2018; 178: 1462-1463.
Ujiie H, Muramatsu K, Mushiroda T, et␣al. HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. J Invest Dermatol 2018; 138: 1201-1204.